Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 8, 2013, Pages 920-925

  Saad, Yasmin ^a   Ahmed, Amal ^b   Saleh, Doa'A A ^a   Doss, Wahid ^a,c  

^a CAIRO UNIVERSITY   (Egypt)

^b Department of Medical Biochemistry ^*  (Egypt)

^c NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

Author keywords

Adiponectin; hepatitis C virus genotype 4; insulin resistance; leptin; sustained virological response

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ASPARTATE AMINOTRANSFERASE; LEPTIN; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; EGYPT; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; INFRARED SPECTROSCOPY; INSULIN RESISTANCE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADIPOKINES; ADIPONECTIN; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON-ALPHA; LEPTIN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; ROC CURVE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84879921877     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835f2726     Document Type: Article

References (62)

1. Dienstag JL, Mc Hutchison JG. American gastroenterological association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:225-230.
2. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, Hamamoto N, et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 2005; 20:204-208.
3. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, Conne B, Pugnale P, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol 2005; 42:744-751.
4. Solis-Herruzo JA, Pérez-Carreras M, Rivas E, Fernández- Vázquez I, Garfia C, Bernardos E, et al. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005; 100:1091-1098.
5. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006; 13:73-80.
6. Gupte P, Dudhade A, Desai HG. Acquired apolipoprotein B deficiency with chronic hepatitis C virus infection. Indian J Gastroenterol 2006; 25:311-312.
7. Iacono O, Venezia G, Petta S. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patientswith chronic hepatitis C. Aliment Pharmacol Ther 2007; 25:1181-1119.
8. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007; 47:142-156.
9. Eguchi Y, Mizuta T, Yasutake T, Hisatomi A, Iwakiri R, Ozaki I, et al. High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C. World J Gastroenterol 2006; 12:556-560.
10. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV, Anania FA. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J2004; 18:1612-1614.
11. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166:1655-1669.
12. Derbala M, Rizk N, Al-Kaabi S, Amer A, Shebl F, Al Marri A, et al. Adiponectin changes in HCV-genotype 4: relation to liver histology and response to treatment. J Viral Hepat 2009; 16:689-696.
13. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Position cloning of the mouse obese gene and its human homologue. Nature 1994; 372:425-432.
14. Spiegelman BM, Flier JS. Obesity and the regulation ofenergy balance. Cell 2001; 104:531-543.
15. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998; 244:178-182.
16. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002; 37:206-213.
17. Bethanis S, Theocharis S. Leptin in the field of hepatic fibrosis: a pivotal or incidental player? Dig Dis Sci 2006; 51:1685-1696.
18. Tsochatzis E, Papatheodoridis GV, Archimandritis AJ. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006; 101:2629-2640.
19. Bolukbas FF, Bolukbas C, Horoz M, Gumus M, Erdogan M, Zeyrek F, et al. Child-Pugh classification dependent alterations in serum leptin levels among cirrhotic patients: a case controlled study. BMC Gastroenterol 2004; 4:23.
20. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000; 95:3584-3588.
21. Ben-Ari Z, Schaffer Z, Sulkes J, Manhaim V, Tur-Kaspa R, Fainaru M. Alterations in serum leptin in chronic liver disease. Dig Dis Sci 2002; 47:183-189.
22. Comlekci A, Akpinar H, Yesil S, Okan I, Ellidokuz E, Okan A, et al. Serum leptin levels in patients with liver cirrhosis and chronic viral hepatitis. Scand J Gastroenterol 2003; 38:779-786.
23. Zainab DM, Ed Wakil A. Hepatitis C in Egypt. Am J Gastroenterol 2006; 94:1018-1022.
24. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report, 2007. Available at: http://www.mohp.gov.eg/Main.asp [Accessed 10 August 2007].
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28:412-41 9.
26. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, De Iasio R. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90:3498-3504.
27. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
28. Esmat G, Abouzied AM, Abdel-Aziz F, Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin [abstract]. Hepatology 2003; 38 (Suppl):324A.
29. Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M. Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [abstract]. Hepatology 2003; 38 (Suppl):996A.
30. Thakeb FAI, Omar MM, El Awadi MM, Isshak SY. Randomized controlled trial of peginterferon alpha-2a plus ribavirin forchronic hepatitis Cvirus genotype 4 among Egyptian patients [abstract]. Hepatology 2003; 38:252A.
31. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99:1733-1 737.
32. Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis Cvirus genotype 4 with peginterferonalpha2a and ribavirin. Ann Intern Med 2004; 140:72-73.
33. Soriano V, Nunez M, Sanchez-Conde M, Barreiro P, Garcia-Samaniego A, Martin-Carbonero L, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antivir Ther 2005; 10:167-170.
34. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, et al. Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis Cvirus genotype 4 infection. J Viral Hepat 2007; 14:460-467.
35. Alberti A. What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C? Liver Int 2009; 29 (Suppl 1):15-18.
36. Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent riskfactorfor nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38:639-644.
37. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:1215-1219.
38. Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta E, et al. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver 1999; 19:432-437.
39. Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? J Hepatol 2001; 35:432-433.
40. Banerjee D, Williams EV, Ilott J, Monypenny IJ, Webster DJ. Obesity predisposes to increased drainage following axillary node clearance: a prospective audit Ann R Coll Surg Engl 2001; 83:268-271.
41. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394:897-901.
42. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002; 123:1070-1083.
43. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008; 52:1201-1210.
44. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Ann Rev Physiol 2008; 70:537-556.
45. Huang JF, Yu ML, Dai CY, Hsieh MY, Hwang SJ, Hsiao PJ, et al. Pretreatment insulin sensitivity contributes to the treatment response to peginterferon plus ribavirin combination therapy for patients with chronic hepatitis C. Hepatology 2007; 46:349A.
46. Bortoletto G, Realdon S, Dal Pero F, Gerotto M, Scribano L., Boninsegna S. Insulin resistance (IR) defined by the homeostasis model of assessment insulin resistance (HOMA-IR) index has a direct effect on early viral kinetics during pegylated-interferon therapy for chronic hepatitis C. Hepatology 2007; 46:361A.
47. Nasta P, Gatti F, Puoti M, Cologni G, Bergamaschi V, Borghi F, et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS 2008; 22:857-861.
48. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641.
49. Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007; 45:80-87.
50. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, et al. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: insulin resistance and response to antiviral therapy. Hepatology 2007; 46:1009-1015.
51. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48:28-34.
52. Chu CJ, Lee SD, Hung TH, Lin HC, Hwang SJ, Lee FY, et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin. Aliment Pharmacol Ther 2009; 29:46-54.
53. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165:1499-1508.
54. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55:529-535.
55. Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, et al. Signalling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 2001; 13:363-373.
56. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54:1003-1008.
57. Romero-Gomez M. Insulin resistance and chronic hepatitis C. World J Gastroenterol 2006; 28:7075-7080.
58. Manolakopoulos S, Bethanis S, Liapi C, Stripeli F, Sklavos P, Margeli A, et al. An assessment of serum leptin levels in patients with chronic viral hepatitis: a prospective study BMC. Gastroenterology 2007; 7:1 7.
59. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw 2006; 17:4-12.
60. Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis Cvirus. Hepatology 2008; 48 (No. 2):374-384.
61. Frese M, Schwarzle V, Barth K, Krieger N, Lohmann V, Mihm S, et al. Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35:694-703.
62. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91.